Lenalidomide: all 818 studies that test it
Page 6 of 9. Open to participants first (111), then studies with results posted, then the rest; newest registration first within each.
- Study of Lenalidomide, Venetoclax and Obinutuzumab in Patients With Treatment-Naïve Follicular LymphomaActive, not recruitingNCT03980171Phase 1/2
- A Study to Desensitize Allergic Reactions to Treatments for Blood DisordersCompletedNCT03959358Phase 2
- TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaCompletedNCT03952091Phase 3
- Study Evaluating the Safety and Efficacy of iR2 in Untreated and Unfit Elderly Patients With DLBCLStatus unknownNCT03949062Phase 2
- Carfilzomib + Lenalidomide and Dexamethasone for BTK Inhibitors Relapsed-refractory or Intolerant MCLStatus unknownNCT03891355Phase 2
- DLCL002 Protocol for Patients With High Risk Aggressive B-cell LymphomaStatus unknownNCT03837873Phase 2
- STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMAActive, not recruitingNCT03829371Phase 4
- Study to Demonstrate Clinical Benefit of Lenalidomide and DexamethasoneActive, not recruitingNCT03809780Phase 2
- Lenalidomide, Rituximab, Gemcitabine, Oxaliplatin and Dexamethasone in Relapse and Refractory DLBCLStatus unknownNCT03795571Phase 1
- A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose TherapyWithdrawnNCT03785184Phase 2
- Ph 2 Maintenance Trial: Ixazomib vs Ixazomib-Lenalidomide for MM PatientsTerminatedNCT03733691Phase 2
- Phase II of Lenalidomide After Salvage Therapy in R/R Non-Hodgkin T-cell LymphomaStatus unknownNCT03730740Phase 2
- Myeloma XIV: Frailty-adjusted Therapy in Transplant Non-Eligible Patients With Newly Diagnosed Multiple MyelomaStatus unknownNCT03720041Phase 3
- R2 in the Treatment of Follicular LymphomaStatus unknownNCT03715309Phase 2
- Ibrutinib With Rituximab and Lenalidomide for Patients With Recurrent/Refractory Primary or Secondary Central Nervous System Lymphoma (PCNSL/SCNSL)CompletedNCT03703167Phase 1
- Lenalidomide in Anti-MAG Neuropathy: Phase 1b StudyTerminatedNCT03701711Phase 1
- Study Association of Lenalidomide, Ixazomib, Dexamethasone and Daratumumab in Newly Diagnosed Standard Risk Multiple MyelomaStatus unknownNCT03669445Phase 2
- Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)CompletedNCT03651128Phase 3
- An Intensive Program With Quadruplet Induction and Consolidation Plus Tandem Autologous Stem Cell Transplantation in Newly Diagnosed High Risk Multiple Myeloma PatientsActive, not recruitingNCT03606577Phase 2
- Phase 2 Trial of Chidamide-Lenalidomide-Dexamethasone(CRD) Regimen in R/R MMStatus unknownNCT03605056Phase 2
- Daratumumab, Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin Hydrochloride, and Lenalidomide in Treating Participants With Plasma Cell LeukemiaWithdrawnNCT03591744Phase 1
- Rituximab, Lenalidomide, and Nivolumab in Treating Participants With Relapsed or Refractory Non-Germinal Center Type Diffuse Large B Cell Lymphoma or Primary Central Nervous System LymphomaTerminatedNCT03558750Phase 1
- A Study of Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Patients With Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell TransplantationActive, not recruitingNCT03556332Phase 2
- Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple MyelomaActive, not recruitingNCT03500445Phase 2
- Study on Tailored Treatment in Elderly Patients With Newly Diagnosed Primary Lymphoma of Central Nervous SystemCompletedNCT03495960Phase 2
- Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHLTerminatedNCT03379051Phase 1/2
- Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory T-Cell LymphomasWithdrawnNCT03373305Phase 1
- Lenalidomide Plus ICE in the Treatment of Refractory and Relapsed DLBCLStatus unknownNCT03367143Phase 2
- Ibrutinib and Lenalidomide in Treating Patients With Myelodysplastic SyndromeCompletedNCT03359460Phase 1
- Brentuximab Vedotin and Lenalidomide in Patients With Relapsed/ Refractory T-cell Lymphoma or Hodgkin LymphomaCompletedNCT03302728Phase 1
- Aggressive Smoldering Curative Approach Evaluating Novel Therapies and TransplantActive, not recruitingNCT03289299Phase 2
- Study of Lenalidomide/Dexamethasone With Nivolumab and Ipilimumab in Patients With Newly Diagnosed Multiple MyelomaWithdrawnNCT03283046Phase 1
- Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular LymphomaActive, not recruitingNCT03269669Phase 2
- Ibrutinib Plus Rituximab and Lenalidomide in Treating Elderly Participants With Newly Diagnosed Mantle Cell LymphomaWithdrawnNCT03232307Phase 2
- Study Of Durvalumab and Lenalidomide In R/R EBV Associated DLBCL Subtypes, Primary CNS And Testicular DLBCLWithdrawnNCT03212807Phase 2
- Crossover Study to Compare Pharmacokinetic Property of SYP-1512 Tab and Revlimid Cap in Healthy Male VolunteersCompletedNCT03208218Phase 1
- Pembrolizumab Cyclophosphamide and Lenalidomide for Patients With Relapsed Multiple MyelomaWithdrawnNCT03191981Phase 1/2
- MUK Nine b: OPTIMUM Treatment ProtocolActive, not recruitingNCT03188172Phase 2
- A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM)TerminatedNCT03173092Phase 4
- 2017-03: A Single-Arm, Open-label Study of Anti-Signaling Lymphocytic Activation Molecule F7 (Anti-SLAMF7) Monoclonal Antibody (mAb) Therapy After Autologous Stem Cell Transplant in Patients With Multiple MyelomaWithdrawnNCT03168100Phase 2
- Obinutuzumab, High Dose Methylprednisolone (HDMP), and Lenalidomide for the Treatment of Patients With Richter's SyndromeCompletedNCT03113695Phase 1
- Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and DexamethasoneActive, not recruitingNCT03104842Phase 2
- Clarithromycin + Lenalidomide Combination: a Full Oral Treatment for Patients With Relapsed/Refractory Extranodal Marginal Zone LymphomaCompletedNCT03031483Phase 2
- Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin LymphomaCompletedNCT03015896Phase 1/2
- Ibrutinib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Ineligible for TransplantTerminatedNCT03015792Phase 1
- 2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance TherapyActive, not recruitingNCT03004287Phase 2
- Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin LymphomaActive, not recruitingNCT02992522Phase 1
- Clarithromycin,Lenalidomide and Dexamethasone for Relapsed/Refractory MyelomaWithdrawnNCT02986451Phase 2
- Therapy of Non-Hodgkin-Lymphoma by Combination of Lenalidomide + Rituximab, Dexa, High-dose ARA-C and CisPTerminatedNCT02983097Phase 1/2
- Ixazomib Citrate, Lenalidomide, and Dexamethasone in Treating Patients With POEMS SyndromeCompletedNCT02921893Early Phase 1
- A Study of JNJ-54767414 (Daratumumab) in Combination With Lenalidomide and Dexamethasone in Japanese Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-dose Therapy and Autologous Stem Cell TransplantationCompletedNCT02918331Phase 1
- Ixazomib, Lenalidomide, Dexamethasone Induction and Extended Consolidation Plus Lenalidomide Maintenance in Multiple MyelomaTerminatedNCT02897830Phase 2
- A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MMActive, not recruitingNCT02886065Phase 1
- Induction Therapy for Multiple Myeloma With Carfilzomib, Lenalidomide,Dexamethasone,PanobinostatWithdrawnNCT02802163Phase 1/2
- Treatment of IgG4-Related Disease With Revlimid and RituximabCompletedNCT02705638Phase 1
- Gossypol Acetic Acid With Lenalidomide and Dexamethasone in Treating Patients With Relapsed Symptomatic Multiple MyelomaCompletedNCT02697344Phase 1
- Trial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple MyelomaActive, not recruitingNCT02659293Phase 3
- Elotuzumab in Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance for Multiple MyelomaCompletedNCT02655458Phase 1
- Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK CellsActive, not recruitingNCT02573896Phase 1
- Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin LymphomaCompletedNCT02568553Phase 1
- Trial of Immunomodulatory Therapy in High Risk Solitary Bone PlasmacytomaActive, not recruitingNCT02544308Phase 3
- Lenalidomide Maintenance in Plasma Cell MyelomaActive, not recruitingNCT02538198Phase 2
- Study to Evaluatethe Bioavailability and Food Effect Lenalidomide as an Oral SuspensionCompletedNCT02521714Phase 1
- Study of Isatuximab Combined With Bortezomib + Cyclophosphamide + Dexamethasone (VCD) and Bortezomib + Lenalidomide + Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) Non Eligible for Transplant or No Intent for Immediate TransplantationCompletedNCT02513186Phase 1
- Azacitidine, Lenalidomide and DLI as Salvage Therapy for MDS, CMML and sAML Relapsing After Allo-HSCTCompletedNCT02472691Phase 2
- Lenalidomide & Adriamycin & Dexamethasone (RAD) in Newly Diagnosed, Multiple Myeloma PatientsCompletedNCT02471820Phase 2
- A Trial of Ibrutinib, Lenalidomide and Rituximab for Patients With Relapsed/Refractory Mantle Cell LymphomaCompletedNCT02460276Phase 2
- Clinical Study of CWP232291 in Relapsed or Refractory Myeloma PatientsCompletedNCT02426723Phase 1
- Elotuzumab and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple MyelomaActive, not recruitingNCT02420860Phase 2
- Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple MyelomaActive, not recruitingNCT02415413Phase 2
- Study of Selinexor (KPT- 330), Lenalidomide, & Dexamethasone in Relapsed/Refractory Multiple Myeloma PatientsWithdrawnNCT02389543Phase 1/2
- Lenalidomide and Obinutuzumab for Previously Untreated CLLWithdrawnNCT02371590Phase 2
- Evaluation of the Immune Restoration Potential Of LenalidomideWithdrawnNCT02371577Phase 2
- Phase III, Randomized Trial: Lenalidomide vs Observation After Induction With Rituximab Followed by Cht and ASCT in MCL Adult PatientsStatus unknownNCT02354313Phase 3
- Open-label Extended Access Program on Lenalidomide Plus Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma Who Participated in CC-5013-MM021 for at Least 1 YearCompletedNCT02348528Phase 2
- SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance TherapyActive, not recruitingNCT02334865Phase 1
- Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic Stem Cell TransplantationCompletedNCT02312102Phase 1
- Study of Lenalidomide in Relapse/Refractory Waldenstrom MacroglobulinemiaCompletedNCT02302469Phase 1/2
- Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin LymphomaWithdrawnNCT02281279Phase 1/2
- Lenalidomide in Combination With Microtransplantation as Post-remission Therapy in AMLTerminatedNCT02255162Phase 1
- Study of the Efficacy and Safety of RsqVD Combination Therapy for Patients With Newly Diagnosed Multiple MyelomaCompletedNCT02219178Phase 2
- STUDY TO DETERMINE THE EFFICACY AND SAFETY OF STANDARD SCHEDULE VERSUS A NEW ALGORITHM OF DOSE REDUCTIONS IN ELDERLY AND UNFIT NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS RECEIVING LENALIDOMIDE PLUS STEROIDSCompletedNCT02215980Phase 3
- Cyclophosphamide With Biochemical Progression During Lenalidomide-Dexamethasone Treatment for Relapsed/Refractory Multiple Myeloma (MM)CompletedNCT02206503Phase 2
- Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma PatientsCompletedNCT02206425Phase 1/2
- Evaluation of the Safety and the Efficacy of Carfilzomib Combined With Cyclophosphamide and Dexamethasone (CCyd) or Lenalidomide and Dex (CRd) Followed by ASCT or 12 Cycles of Carf Combined With Dex and Len for Patients Eligible for ASCT With Newly Diagnosed Multiple Myeloma.CompletedNCT02203643Phase 2
- Phase I Study of Lenalidomide, Rituximab and Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)TerminatedNCT02200848Phase 1
- Efficacy and Safety of Lenalidomide as a Treatment for Recurrent or Refractory POEMS Syndrome TrialCompletedNCT02193698Phase 2
- Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by SurgeryActive, not recruitingNCT02160015Phase 1
- Continuous Lenalidomide Therapy Versus Observation Following Induction Without Lenalidomide, Pomalidomide or Thalidomide in MyelomaWithdrawnNCT02155634Phase 3
- Treatment Optimization in Patients With Untreated Multiple MyelomaTerminatedNCT02145598Phase 2/3
- Efficacy of Lenalidomide in Combination With Subcutaneous Rituximab + miniCHOP in DLBCL Patients of 80 y/o or+CompletedNCT02128061Phase 3
- Lenalidomide vs Placebo Maintenance Therapy Following Melphalan Prednisone Velcade® Induction Therapy in NDMMCompletedNCT02112175Phase 3
- Brentuximab Vedotin and Lenalidomide for Relapsed or Refractory Diffuse Large B-cell LymphomaCompletedNCT02086604Phase 1
- Lenalidomide and Pidilizumab in Treating Patients With Relapsed or Refractory Multiple MyelomaTerminatedNCT02077959Phase 1
- Phase II Study Comparing LR-GEM to R-GEM-P in Second-line Treatment of Diffuse Large B-cell Lymphoma (LEGEND)Status unknownNCT02060656Phase 2
- Palbociclib in Combination With Lenalidomide and Dexamethasone for Multiple MyelomaTerminatedNCT02030483Phase 1
- Lenalidomide Maintenance Therapy in Stage IIIB/IV Non-small Cell Lung CancerTerminatedNCT02018523Phase 1
- Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLLCompletedNCT02005289Phase 2
- A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple MyelomaCompletedNCT01998971Phase 1
- A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple MyelomaCompletedNCT01965353Phase 1